Evidence map›Paper›PMID 41246083›Full record

ReviewFrontiers in public health2025

The global response to HIV/AIDS in sub-Saharan Africa: achievements, challenges, and perspectives for the future.

Stefano Orlando, Loredana Andreea Silaghi, Mariagrazia Cicala, Mathambo William Lowole, Cacilda Massango, Roberto Lunghi, Hawa Sangarè Mamary, Fausto Ciccacci, Paola Scarcella

Abstract readReview
In one paragraph

Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stefano OrlandoDepartment of Biomedicine and Prevention, Università degli Studi di Roma Tor Vergata, Rome, Italy.
Loredana Andreea SilaghiDepartment of Biomedicine and Prevention, Università degli Studi di Roma Tor Vergata, Rome, Italy.
Mariagrazia CicalaDepartment of Biomedicine and Prevention, Università degli Studi di Roma Tor Vergata, Rome, Italy.
Mathambo William LowoleCommunity of Sant'Egidio, DREAM Programme, Lilongwe, Malawi.
Cacilda MassangoCommunity of Sant'Egidio, DREAM Programme, Maputo, Mozambique.
Roberto LunghiCommunity of Sant'Egidio, DREAM Programme, Rome, Italy.
Hawa Sangarè MamaryCommunity of Sant'Egidio, DREAM Programme, Lilongwe, Malawi.
Fausto CiccacciDepartment of Biomedicine and Prevention, Università degli Studi di Roma Tor Vergata, Rome, Italy.
Paola ScarcellaLibera Università Maria Ss. Assunta (LUMSA), Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over four decades, the global response to HIV/AIDS has transformed the disease into a manageable chronic condition, driven by advances in antiretroviral therapy, global financing, and ambitious targets like the 90-90-90 and 95-95-95 goals. Yet HIV remains a major challenge, especially in sub-Saharan Africa, which bears the highest burden worldwide. While AIDS-related mortality has declined, the number of people living with HIV continues to grow, placing significant strain on health systems and financial resources. Persistent challenges include high rates of new infections, late diagnoses, inequalities in access to care, and barriers faced by key populations. Emerging issues such as drug resistance and declining political commitment risk reversing progress. Investments in HIV have yielded broader benefits for health systems, supporting integration with services for tuberculosis and noncommunicable diseases. This review traces the global HIV response, analyses current epidemiological and economic trends, and highlights strategic priorities to sustain progress. Key strategic directions include reducing costs and expanding access to advanced diagnostics and antiretroviral therapy; prioritizing comprehensive, high-quality care over simplified delivery models that risk compromising diagnostic accuracy and fostering drug resistance; integrating HIV programs with services for other diseases, including noncommunicable diseases; strengthening surveillance and management of HIV drug resistance; and sustaining the visibility of HIV while addressing the needs of marginalized populations.

Indexed as

Acquired Immunodeficiency SyndromeGlobal HealthHIV InfectionsAfrica South of the SaharaHealth Services AccessibilityHumansdifferentiated service delivery (DSD)health financingHIVHIV inequalitiessub-Saharan Africa

Identifiers

PMID41246083
PMCPMC12615466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.